Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 20%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics is well-positioned in the market due to its unique product, the iLet Bionic Pancreas, which aims to improve the treatment of diabetes for patients. The company's recent sales growth, increased guidance, and expansion of its sales force highlight the strong potential for revenue growth in the coming years. With steady beats and raises to results and guidance and potential upcoming momentum around the company's semi-durable patch pump, Beta Bionics is a compelling investment opportunity for those with a positive outlook on the company's potential.

Bears say

Beta Bionics is facing challenges in potential commercialization with their iLet Bionic Pancreas device as demonstrated through their lowered sales outlook for ’27 and increasing cash burn. Despite a strong first quarter and positive commentary on their Mint patch product, the stock is under pressure due to broader negative sentiment towards small cap med tech companies. While the iLet Bionic Pancreas has the potential to improve outcomes for PWDs, the limited market and competitive landscape may hinder its success and make it a risky investment at this time.

BBNX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 20% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 10 analysts, BBNX has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.